Top

Published in:

01-08-2019 | Hepatitis C | ORIGINAL ARTICLE

TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response

Authors: Feng Zheng, Nannan Xu, Yajun Zhang

Published in: Inflammation | Issue 4/2019

Abstract

Type I interferon (IFN) response is central for host defense against viral infection. Tripartite motif 27 (TRIM27) is implicated in antiviral innate immune response; however, whether it affects the replication of hepatitis C virus (HCV) and the underlying mechanisms remain uncharacterized. Here, we show that TRIM27 expression is induced in Huh7.5 human hepatoma cells infected with HCV or stimulated with type I IFNs in vitro. In addition, TRIM27 overexpression increases and its knockdown decreases viral RNA and protein levels, suggesting that TRIM27 positively regulates HCV replication. Mechanistically, TRIM27 inhibits type I IFN response against HCV infection through inhibiting IRF3 and NF-κB pathways, since TRIM27 mutant unable to inhibit these two inflammatory pathways fails to promote HCV replication. Taken together, this study identifies TRIM27 as a novel positive regulator of HCV replication, and also implicates that targeting TRIM27 may serve as a therapeutic strategy for controlling HCV replication.

Netea, M.G., L.A. Joosten, E. Latz, K.H. Mills, G. Natoli, H.G. Stunnenberg, L.A. O’Neill, and R.J. Xavier. 2016. Trained immunity: a program of innate immune memory in health and disease. Science 352 (6284): aaf1098. https://doi.org/10.1126/science.aaf1098.CrossRefPubMedPubMedCentral

Brubaker, S.W., K.S. Bonham, I. Zanoni, and J.C. Kagan. 2015. Innate immune pattern recognition: a cell biological perspective. Annual Review of Immunology 33: 257–290. https://doi.org/10.1146/annurev-immunol-032414-112240.CrossRefPubMedPubMedCentral

Reddick, L.E., and N.M. Alto. 2014. Bacteria fighting back: how pathogens target and subvert the host innate immune system. Molecular Cell 54 (2): 321–328. https://doi.org/10.1016/j.molcel.2014.03.010.CrossRefPubMedPubMedCentral

Cao, X. 2016. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nature Reviews Immunology 16 (1): 35–50. https://doi.org/10.1038/nri.2015.8.CrossRefPubMed

Kumar, H., T. Kawai, and S. Akira. 2011. Pathogen recognition by the innate immune system. International Reviews of Immunology 30 (1): 16–34. https://doi.org/10.3109/08830185.2010.529976.CrossRefPubMed

Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140 (6): 805–820. https://doi.org/10.1016/j.cell.2010.01.022.CrossRefPubMed

Czerkies, M., Z. Korwek, W. Prus, M. Kochanczyk, J. Jaruszewicz-Blonska, K. Tudelska, S. Blonski, M. Kimmel, A.R. Brasier, and T. Lipniacki. 2018. Cell fate in antiviral response arises in the crosstalk of IRF, NF-kappaB and JAK/STAT pathways. Nature Communications 9 (1): 493. https://doi.org/10.1038/s41467-017-02640-8.CrossRefPubMedPubMedCentral

McNab, F., K. Mayer-Barber, A. Sher, A. Wack, and A. O’Garra. 2015. Type I interferons in infectious disease. Nature Reviews Immunology 15 (2): 87–103. https://doi.org/10.1038/nri3787.CrossRefPubMedPubMedCentral

Gower, E., C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 61 (1 Suppl): S45–S57. https://doi.org/10.1016/j.jhep.2014.07.027.CrossRefPubMed

10.

AASLD/IDSA HCV Guidance Panel. 2015. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (3): 932–954. https://doi.org/10.1002/hep.27950.CrossRef

11.

Saadoun, D., M. Resche Rigon, V. Thibault, M. Longuet, S. Pol, F. Blanc, G. Pialoux, A. Karras, D. Bazin-Karra, C. Cazorla, D. Vittecoq, L. Musset, O. Decaux, J.M. Ziza, O. Lambotte, and P. Cacoub. 2014. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 73 (5): 831–837. https://doi.org/10.1136/annrheumdis-2012-202770.CrossRefPubMed

12.

Scheel, T.K., and C.M. Rice. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine 19 (7): 837–849. https://doi.org/10.1038/nm.3248.CrossRefPubMedPubMedCentral

13.

Hatakeyama, S. 2017. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends in Biochemical Sciences 42 (4): 297–311. https://doi.org/10.1016/j.tibs.2017.01.002.CrossRefPubMed

14.

Zheng, Q., J. Hou, Y. Zhou, Y. Yang, B. Xie, and X. Cao. 2015. Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27. Cell Research 25 (10): 1121–1136. https://doi.org/10.1038/cr.2015.108.CrossRefPubMedPubMedCentral

15.

Zheng, Q., J. Hou, Y. Zhou, Y. Yang, and X. Cao. 2016. Type I IFN-inducible downregulation of microRNA-27a feedback inhibits antiviral innate response by upregulating Siglec1/TRIM27. Journal of Immunology 196 (3): 1317–1326. https://doi.org/10.4049/jimmunol.1502134.CrossRef

16.

Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.G. Krausslich, M. Mizokami, R. Bartenschlager, and T.J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine 11 (7): 791–796. https://doi.org/10.1038/nm1268.CrossRefPubMedPubMedCentral

17.

Lindenbach, B.D., M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, T. Maruyama, R.O. Hynes, D.R. Burton, J.A. McKeating, and C.M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309 (5734): 623–626. https://doi.org/10.1126/science.1114016.CrossRefPubMed

18.

Zhang, H.X., Z.S. Xu, H. Lin, M. Li, T. Xia, K. Cui, S.Y. Wang, Y. Li, H.B. Shu, and Y.Y. Wang. 2018. TRIM27 mediates STAT3 activation at retromer-positive structures to promote colitis and colitis-associated carcinogenesis. Nature Communications 9 (1): 3441. https://doi.org/10.1038/s41467-018-05796-z.CrossRefPubMedPubMedCentral

19.

Zhou, Z., X. Jia, Q. Xue, Z. Dou, Y. Ma, Z. Zhao, Z. Jiang, B. He, Q. Jin, and J. Wang. 2014. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-I-like receptor-mediated innate immune response. Proceedings of the National Academy of Sciences of the United States of America 111 (2): E245–E254. https://doi.org/10.1073/pnas.1316941111.CrossRefPubMed

20.

Ploss, A., M.J. Evans, V.A. Gaysinskaya, M. Panis, H. You, Y.P. de Jong, and C.M. Rice. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457 (7231): 882–886. https://doi.org/10.1038/nature07684.CrossRefPubMedPubMedCentral

21.

Feld, J.J., and J.H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (7053): 967–972. https://doi.org/10.1038/nature04082.CrossRefPubMed

22.

Wong, M.T., and S.S. Chen. 2016. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cellular & Molecular Immunology 13 (1): 11–35. https://doi.org/10.1038/cmi.2014.127.CrossRef

23.

Bartenschlager, R., F. Penin, V. Lohmann, and P. Andre. 2011. Assembly of infectious hepatitis C virus particles. Trends in Microbiology 19 (2): 95–103. https://doi.org/10.1016/j.tim.2010.11.005.CrossRefPubMed

24.

Marcello, T., A. Grakoui, G. Barba-Spaeth, E.S. Machlin, S.V. Kotenko, M.R. MacDonald, and C.M. Rice. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131 (6): 1887–1898. https://doi.org/10.1053/j.gastro.2006.09.052.CrossRefPubMed

25.

Jiang, Z., T.W. Mak, G. Sen, and X. Li. 2004. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proceedings of the National Academy of Sciences of the United States of America 101 (10): 3533–3538. https://doi.org/10.1073/pnas.0308496101.CrossRefPubMedPubMedCentral

26.

Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends in Molecular Medicine 13 (11): 460–469. https://doi.org/10.1016/j.molmed.2007.09.002.CrossRefPubMed

27.

Conwell, S.E., A.E. White, J.W. Harper, and D.M. Knipe. 2015. Identification of TRIM27 as a novel degradation target of herpes simplex virus 1 ICP0. Journal of Virology 89 (1): 220–229. https://doi.org/10.1128/JVI.02635-14.CrossRefPubMed

28.

Wang, J., J.L. Teng, D. Zhao, P. Ge, B. Li, P.C. Woo, and C.H. Liu. 2016. The ubiquitin ligase TRIM27 functions as a host restriction factor antagonized by Mycobacterium tuberculosis PtpA during mycobacterial infection. Scientific Reports 6: 34827. https://doi.org/10.1038/srep34827.CrossRefPubMedPubMedCentral

29.

Chen, Y., S. Wang, Z. Yi, H. Tian, R. Aliyari, Y. Li, G. Chen, P. Liu, J. Zhong, X. Chen, P. Du, L. Su, F.X. Qin, H. Deng, and G. Cheng. 2014. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Scientific Reports 4: 7242. https://doi.org/10.1038/srep07242.CrossRefPubMedPubMedCentral

30.

Nisole, S., J.P. Stoye, and A. Saib. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nature Reviews Microbiology 3 (10): 799–808. https://doi.org/10.1038/nrmicro1248.CrossRefPubMed

31.

Taylor, R.T., K.J. Lubick, S.J. Robertson, J.P. Broughton, M.E. Bloom, W.A. Bresnahan, and S.M. Best. 2011. TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host & Microbe 10 (3): 185–196. https://doi.org/10.1016/j.chom.2011.08.004.CrossRef

32.

Asaoka, K., K. Ikeda, T. Hishinuma, K. Horie-Inoue, S. Takeda, and S. Inoue. 2005. A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochemical and Biophysical Research Communications 338 (4): 1950–1956. https://doi.org/10.1016/j.bbrc.2005.10.173.CrossRefPubMed

33.

Wang, S., Y. Chen, C. Li, Y. Wu, L. Guo, C. Peng, Y. Huang, G. Cheng, and F.X. Qin. 2016. TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein. Scientific Reports 6: 32336. https://doi.org/10.1038/srep32336.CrossRefPubMedPubMedCentral

Title: TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response
Authors: Feng Zheng
Nannan Xu
Yajun Zhang
Publication date: 01-08-2019
Publisher: Springer US
Keywords: Hepatitis C
Interferon
Published in: Inflammation / Issue 4/2019
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-019-00992-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

TRIM27 Promotes Hepatitis C Virus Replication by Suppressing Type I Interferon Response

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Heteroleptic Ruthenium Polypyridyl Complex Had Differential Effects on the Production of Pro-inflammatory Cytokines TNFα, IL1β, and IL6 by the Mammalian Macrophages In Vitro

Pro-inflammatory S100A9 Protein: a Double-Edged Sword in Cancer?

Interleukin-1β Induces Intracellular Serum Amyloid A1 Expression in Human Coronary Artery Endothelial Cells and Promotes its Intercellular Exchange

Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Ameliorates the Inflammatory Response in Periodontal Disease

Aquaporin 4 Blockade Attenuates Acute Lung Injury Through Inhibition of Th17 Cell Proliferation in Mice

CTRP3 Alleviates Ox-LDL–Induced Inflammatory Response and Endothelial Dysfunction in Mouse Aortic Endothelial Cells by Activating the PI3K/Akt/eNOS Pathway

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page